Table 1 Describe the distribution of various clinicopathological variables with leptin immunostaining in breast cancer

73

16.3%

274

61.0%

102

22.7%

0.0778

2

7.4%

14

51.9%

11

40.7%

16

23.2%

30

43.5%

23

33.3%

0.0233

16

14.0%

67

58.8%

31

27.2%

24

17.9%

89

66.4%

21

15.7%

11

16.2%

46

67.6%

11

16.2%

6

11.8%

31

60.8%

14

27.5%

0

0.0%

11

84.6%

2

15.4%

16

23.2%

36

52.2%

17

24.6%

0.0021

6

8.8%

40

58.8%

22

32.4%

0

0.0%

2

28.6%

5

71.4%

0

0.0%

7

77.8%

2

22.2%

7

14.0%

33

66.0%

10

20.0%

3

17.6%

11

64.7%

3

17.6%

34

23.6%

81

56.3%

29

20.1%

7

8.2%

64

75.3%

14

16.5%

22

14.4%

85

55.6%

46

30.1%

0.0279

51

17.2%

189

63.9%

56

18.9%

32

15.7%

120

58.8%

52

25.5%

0.4410

41

16.7%

154

62.9%

50

20.4%

57

21.1%

152

56.3%

61

22.6%

0.0021

16

8.9%

122

68.2%

41

22.9%

33

17.8%

100

54.1%

52

28.1%

0.0300

40

15.2%

174

65.9%

50

18.9%

10

16.7%

34

56.7%

16

26.7%

0.5784

13

12.0%

68

63.0%

27

25.0%

50

17.8%

172

61.2%

59

21.0%

13

17.8%

42

57.5%

18

24.7%

0.0500

45

18.8%

151

63.2%

43

18.0%

15

10.9%

81

59.1%

41

29.9%

4

23.5%

9

52.9%

4

23.5%

0.0001

65

15.9%

255

62.2%

90

22.0%

0

0.0%

1

11.1%

8

88.9%

4

30.8%

9

69.2%

0

0.0%

8

16.0%

27

54.0%

15

30.0%

0.0291

24

18.3%

69

52.7%

38

29.0%

22

15.8%

92

66.2%

25

18.0%

4

6.1%

49

74.2%

13

19.7%

15

23.8%

37

58.7%

11

17.5%

55

17.8%

184

59.5%

70

22.7%

0.4058

18

12.9%

90

64.3%

32

22.9%

57

14.3%

253

63.4%

89

22.3%

0.0023

16

32.0%

21

42.0%

13

26.0%